Jeuveau® Has Been The Subject Of Extensive Clinical Studies
In U.S. clinical studies, 68% and 70% of Jeuveau® patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30 as compared to 1% for placebo.3 (In regular English? Both injectors and patients saw significantly improved results 30 days after treatment.)
In the largest head-to-head phase III study in frown lines, Jeuveau® demonstrated non-inferiority to Botox® Cosmetic.2*
But that's not all. In the same study, which was study conducted in Europe and Canada, 54% of patients had visible results with at least a 1-grade improvement as early as 2 days after treatment.** And at an impressive 4 months after treatment, 58% of patients still had visible results with Jeuveau®.***
*A non-inferiority study is conducted to show that the effect of a treatment is not worse than the original treatment.
**About 50% of patients begin showing improvement after two days (≥1-grade improvement by physician assessment).2 Most patients (~69%) achieve complete results by day 30 (≥2-grade improvement by physician and patient assessments).3
***Compared to 13% placebo, based on ≥ 1-grade improvement by physician assessment at Day 120.2 Results based on a 1-grade improvement may not be considered clinically meaningful. On average, Jeuveau® patients receive 3 treatments a year.1
Botox® Cosmetic is prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows in adults. BOTOX is a registered trademark of Allergan, Inc.